7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Platelet-rich plasma injections and the development of cutaneous sarcoid lesions: A case report

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Sarcoidosis is a systemic disorder characterized by noncaseating granulomas that most commonly affect the lungs but may also affect the skin, lymph nodes, joints, and eyes. Skin manifestations of sarcoidosis can occur at sites of cutaneous injections with foreign materials including tattoos, insulin injections, and cosmetic fillers. 1 We report the first case of cutaneous sarcoid lesions developing at nonforeign material injection sites in a patient who received platelet-rich plasma (PRP) therapy with no previous history of injections with foreign materials. Case report A 62-year-old Chilean woman with a medical history of uveitis presented with a 3-year history of firm asymptomatic nodules on her face (Fig 1) and right shoulder (Fig 2). These lesions developed at injection sites 4 months after PRP treatment for a right rotator cuff injury as well as injections in the supraciliary region, nasolabial folds, bilateral cheeks, and upper lip for cosmesis. Fig 1 A, Well-defined reddish-brown erythematous plaques and nodules in glabellar and superior brows bilaterally. B, Multiple punctate ulcers with extrusion of xerotic keratinized substance on the jawline. Fig 2 Multiple pink erythematous plaques and flesh-colored subcutaneous nodules on the right shoulder. Ultrasonography found granulomas distributed throughout the injected regions. Punch biopsies from 2 sites found chronic inflammatory processes with foreign body sarcoid granulomas (Fig 3). At this time, PRP injections were stopped. Two years later, repeat soft tissue ultrasonography showed an increase in the number of nodules, 35 on the face and 5 on the right shoulder. Fig 3 Noncaseating epithelioid granulomas with surrounding perivascular lymphocytic infiltrate. There is an extension of infiltrate into the deep subcutaneous space. No evidence of vasculitis. The patient denied fevers, dyspnea, fatigue, loss of appetite, night sweats, unintentional weight loss or gain, edema, cardiac issues, or systemic symptoms. General laboratory studies, including complete blood count, comprehensive metabolic panel, urine analysis, lipid profile, and serum angiotensin-converting enzyme were within normal limits. QuantiFERON and herpes simplex virus serology were negative. On chest computed tomography, multiple symmetric lymph nodes were found in the mediastinum. The patient had an endobronchial ultrasound on 2 hilar and 1 subcarinal lymph nodes, all of which were negative for pathologic conditions. Lymphoid elements were found in different stages of maturation with fibro hyaline nodules consisting of noncaseating granulomas, suggestive of sarcoidosis. In February 2019, the patient refused any form of treatment, and the lesions remained stable. In September 2019, the patient agreed to receive intralesional corticosteroid injections, which yielded little response. The patient recently started on oral corticosteroids and is being followed up for response. Discussion We describe a patient who had sarcoid lesions at sites of PRP injections. This case produces important clinical concerns about the use of PRP in patients with sarcoidosis. We hypothesize that skin trauma elicited a Koebnerization phenomenon that led to cutaneous sarcoid lesions. Compared with whole blood, PRP is an autologous plasma that contains an increased platelet concentration. PRP injections have been beneficial in many dermatologic applications and are often used for skin rejuvenation procedures. 2 Additionally, PRP has been used as an adjuvant treatment to augment musculoskeletal tissue healing. 3 Serizawa et al 4 describe a case of a 68-year-old Japanese woman who had sarcoid skin lesions after treatment with PRP. In addition to PRP treatment, however, this patient had a history of receiving hyaluronic acid and botulinum toxin injections. The introduction of foreign material, such as silica and hyaluronic acid, has been reported previously to trigger cutaneous sarcoidosis. 5 They suggest that injections of PRP may lead to the stimulation of growth factors and the activation and migration of monocytes, which trigger the formation of cutaneous sarcoid granulomas. 6 In contrast to the case by Serizawa et al, 4 our patient received PRP injections only, having no previous history of injections with foreign substances. Although Serizawa et al suggests a link between PRP and granuloma formation, we speculate that the formation of sarcoidosis at PRP injection sites is caused by the skin injury from the injection itself; a Koebnerization reaction. Cutaneous sarcoidosis develops at sites of skin trauma. 7 Chesner et al 8 describe a case of a patient with cutaneous sarcoidosis who was treated with broadband light therapy. The patient developed bullae, which triggered a Koebnerization response, leading to the formation of new sarcoid plaques. We hypothesize that skin trauma secondary to PRP injections triggered the formation of cutaneous sarcoid lesions in our patient. An important clinical consideration in our case is whether the patient had subclinical sarcoidosis prior to PRP treatment. She had a medical history of uveitis, years before the PRP treatment was initiated. Uveitis is found to be the most common ocular manifestation of sarcoidosis and is present in 20% to 50% of sarcoidosis patients. Patients may also present with ocular sarcoidosis in the absence of any other systemic involvement. 9 Given the patient's history of uveitis, we believe that the patient had systemic sarcoidosis that was previously undetected. Topical or intralesional corticosteroids are first-line therapy for localized and mild sarcoidosis limited to the skin. 7 Oral corticosteroids are the drug of choice for rapidly progressive or topical therapy-unresponsive lesions. Treatment is not necessary for all patients with sarcoidosis, as the disease can remain stable or spontaneously remit, and the effect of organ involvement may not justify the risk of drug-induced complications. As well, patients with inadequate responses to corticosteroid therapy are candidates for systemic treatment with antimalarial drugs, methotrexate, or tetracyclines. Because of the complicated nature of the disease and the wide range of symptoms with which sarcoidosis can present, there is unfortunately no single test for the diagnosis or exclusion of sarcoidosis. In patients who present with symptoms concerning for sarcoidosis, further evaluation may be warranted before proceeding with PRP injections. Bronchoscopy with biopsy remains one of the most common procedures for detection of granulomas. 10 In our case, biopsy from facial lesions as well as endobronchial ultrasound scan with needle aspiration found noncaseating granulomas, confirming a diagnosis of sarcoidosis. Conclusion This case report should caution physicians about the use of PRP injections in patients with active sarcoidosis. Appearance of new sarcoid lesions at sites of PRP injections may be suggestive of a Koebnerization reaction to the injection itself. If sarcoidosis is suspected in patients considering PRP treatment, further investigation including bronchopulmonary evaluation of lesions may be warranted to differentiate the type of granulomas present, prior to proceeding with PRP.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Platelet-rich therapies for musculoskeletal soft tissue injuries.

          Platelet-rich therapies are being used increasingly in the treatment of musculoskeletal soft tissue injuries such as ligament, muscle and tendon tears and tendinopathies. These therapies can be used as the principal treatment or as an augmentation procedure (application after surgical repair or reconstruction). Platelet-rich therapies are produced by centrifuging a quantity of the patient's own blood and extracting the active, platelet-rich, fraction. The platelet-rich fraction is applied to the injured tissue; for example, by injection. Platelets have the ability to produce several growth factors, so these therapies should enhance tissue healing. There is a need to assess whether this translates into clinical benefit. To assess the effects (benefits and harms) of platelet-rich therapies for treating musculoskeletal soft tissue injuries. We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (25 March 2013), the Cochrane Central Register of Controlled Trials (CENTRAL 2013 Issue 2), MEDLINE (1946 to March 2013), EMBASE (1980 to 2013 Week 12) and LILACS (1982 to March 2012). We also searched trial registers (to Week 2 2013) and conference abstracts (2005 to March 2012). No language or publication restrictions were applied. We included randomised and quasi-randomised controlled trials that compared platelet-rich therapy with either placebo, autologous whole blood, dry needling or no platelet-rich therapy for people with acute or chronic musculoskeletal soft tissue injuries. Primary outcomes were functional status, pain and adverse effects. Two review authors independently extracted data and assessed each study's risk of bias. Disagreement was resolved by discussion or by arbitration by a third author. We contacted trial authors for clarification of methods or missing data. Treatment effects were assessed using risk ratios for dichotomous data and mean differences (MD) or standardised mean differences (SMD) for continuous data, together with 95% confidence intervals. Where appropriate, data were pooled using the fixed-effect model for RR and MD, and the random-effects model for SMD. The quality of the evidence for each outcome was assessed using GRADE criteria. We included data from 19 small single centre trials (17 randomised and two quasi-randomised; 1088 participants) that compared platelet-rich therapy with placebo, autologous whole blood, dry needling or no platelet-rich therapy. These trials covered eight clinical conditions: rotator cuff tears (arthroscopic repair) (six trials); shoulder impingement syndrome surgery (one trial); elbow epicondylitis (three trials); anterior cruciate ligament (ACL) reconstruction (four trials), ACL reconstruction (donor graft site application) (two trials), patellar tendinopathy (one trial), Achilles tendinopathy (one trial) and acute Achilles rupture surgical repair (one trial). We also grouped trials into 'tendinopathies' where platelet-rich therapy (PRT) injections were the main treatment (five trials), and surgical augmentation procedures where PRT was applied during surgery (14 trials). Trial participants were mainly male, except in trials including rotator cuff tears, and elbow and Achilles tendinopathies.Three trials were judged as being at low risk of bias; the other 16 were at high or unclear risk of bias relating to selection, detection, attrition or selective reporting, or combinations of these. The methods of preparing platelet-rich plasma (PRP) varied and lacked standardisation and quantification of the PRP applied to the patient.We were able to pool data for our primary outcomes (function, pain, adverse events) for a maximum of 11 trials and 45% of participants. The evidence for all primary outcomes was judged as being of very low quality.Data assessing function in the short term (up to three months) were pooled from four trials that assessed PRT in three clinical conditions and used four different measures. These showed no significant difference between PRT and control (SMD 0.26; 95% confidence interval (CI) -0.19 to 0.71; P value 0.26; I² = 51%; 162 participants; positive values favour PRT). Medium-term function data (at six months) were pooled from five trials that assessed PRT in five clinical conditions and used five different measures. These also showed no difference between groups (SMD -0.09, 95% CI -0.56 to 0.39; P value 0.72; I² = 50%; 151 participants). Long-term function data (at one year) were pooled from 10 trials that assessed PRT in five clinical conditions and used six different measures. These also showed no difference between groups (SMD 0.25, 95% CI -0.07 to 0.57; P value 0.12; I² = 66%; 484 participants). Although the 95% confidence intervals indicate the possibility of a poorer outcome in the PRT group up to a moderate difference in favour of PRT at short- and long-term follow-up, these do not translate into clinically relevant differences.Data pooled from four trials that assessed PRT in three clinical conditions showed a small reduction in short-term pain in favour of PRT on a 10-point scale (MD -0.95, 95% CI -1.41 to -0.48; I² = 0%; 175 participants). The clinical significance of this result is marginal.Four trials reported adverse events; another seven trials reported an absence of adverse events. There was no difference between treatment groups in the numbers of participants with adverse effects (7/241 versus 5/245; RR 1.31, 95% CI 0.48 to 3.59; I² = 0%; 486 participants).In terms of individual conditions, we pooled heterogeneous data for long-term function from six trials of PRT application during rotator cuff tear surgery. This showed no statistically or clinically significant differences between the two groups (324 participants).The available evidence is insufficient to indicate whether the effects of PRT will differ importantly in individual clinical conditions. Overall, and for the individual clinical conditions, there is currently insufficient evidence to support the use of PRT for treating musculoskeletal soft tissue injuries. Researchers contemplating RCTs should consider the coverage of currently ongoing trials when assessing the need for future RCTs on specific conditions. There is need for standardisation of PRP preparation methods.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease.

            Sarcoidosis is a common systemic, noncaseating granulomatous disease of unknown etiology. The development of sarcoidosis has been associated with a number of environmental factors and genes. Cutaneous sarcoidosis, the "great imitator," can baffle clinicians because of its diverse manifestations and its ability to resemble both common and rare cutaneous diseases. Depending on the type, location, and distribution of the lesions, treatment can prevent functional impairment, symptomatic distress, scarring, and disfigurement. Numerous therapeutic options are available for the treatment of cutaneous sarcoidosis, but there are few well designed trials to guide practitioners on evidence-based, best practice management. In part I, we review the current knowledge and advances in the epidemiology, etiology, pathogenesis, and genetics of sarcoidosis, discuss the heterogeneous manifestations of cutaneous sarcoidosis, and provide a guide for treatment of cutaneous sarcoidosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sarcoidosis and uveitis.

              Uveitis is a frequent (20-50%) and early feature of sarcoidosis. Typical sarcoid uveitis presents with mutton-fat keratic precipitates, iris nodules, and anterior and posterior synechiae. Posterior involvement includes vitreitis, vasculitis, and choroidal lesions. Cystoid macular edema is the most important and sight-threatening consequence. Histologic proof from a biopsy is the gold standard for the diagnosis of ocular sarcoidosis. An international workshop has recently established diagnostic criteria for sarcoidosis uveitis when biopsy is unavailable or negative: these are based on a combination of ophthalmological findings and laboratory tests. The value of recent techniques, such as PET-scan and endoscopic ultrasound-guided, fine-needle aspiration of intrathoracic nodes needs to be assessed in future studies. Corticosteroids are the mainstay treatment for sarcoidosis. Systemic corticosteroids are indicated when uveitis does not respond to topical corticosteroids or when there is bilateral posterior involvement, especially macular edema and occlusive vasculitis. In up to 15% of cases, additional immunosuppression is used, including methotrexate, azathioprine, and mycophenolate mofetil. Infliximab and adalimumab have been recently proposed for the treatment of refractory or sight-threatening systemic sarcoidosis.
                Bookmark

                Author and article information

                Contributors
                Journal
                JAAD Case Rep
                JAAD Case Rep
                JAAD Case Reports
                Elsevier
                2352-5126
                25 March 2020
                April 2020
                25 March 2020
                : 6
                : 4
                : 348-350
                Affiliations
                [a ]Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
                [b ]Department of Dermatology, Larkin Community Hospital Palm Springs Campus, Hialeah, Florida
                [c ]Department of Plastic Surgery, Clínica Las Condes, Santiago, Chile
                [d ]Department of Dermatology, Clínica Las Condes, Santiago, Chile
                [e ]Department of Dermatology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
                Author notes
                []Correspondence to: Nicole Izhakoff, BA, Herbert Wertheim College of Medicine, Florida International University, 2200 NE 201 st Street, Miami, FL 33180. nizha001@ 123456fiu.edu
                Article
                S2352-5126(20)30125-9
                10.1016/j.jdcr.2020.02.009
                7103666
                32258318
                075f9b67-62ba-434b-962e-895e1f36b41a
                © 2020 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Case Report

                cutaneous nodules,cutaneous sarcoid,cutaneous sarcoidosis,platelet-rich plasma,sarcoidosis,prp, platelet-rich plasma

                Comments

                Comment on this article